Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels
- 05.01.2022
- Gastrointestinal Oncology
Erschienen in:
- Verfasst von
- Ankit Dhiman, MBBS, MS
- Charles C. Vining, MD
- Hunter D. D. Witmer, MD
- Divya Sood, MD
- Ardaman Shergill, MD
- Hedy Kindler, MD
- Kevin K. Roggin, MD
- Mitchell C. Posner, MD
- Osmanuddin S. Ahmed, MD
- Stanley Liauw, MD
- Sean Pitroda, MD
- Chih-Yi Liao, MD
- Theodore Karrison, PhD
- Ralph Weichselbaum, MD
- Blase Polite, MD
- Oliver S. Eng, MD
- Daniel V. T. Catenacci, MD
- Kiran K. Turaga, MD, MPH
- Erschienen in
- Annals of Surgical Oncology | Ausgabe 7/2022
Abstract
Background
Metastatic adenocarcinomas of foregut origin are aggressive and have limited treatment options, poor quality of life, and a dismal prognosis. A subset of such patients with limited metastatic disease might have favorable outcomes with locoregional metastasis-directed therapies. This study investigates the role of sequential cytoreductive interventions in addition to the standard of care chemotherapy in patients with oligometastatic foregut adenocarcinoma.
Methods
This is a single-center, phase II, open-label randomized clinical trial. Eligible patients include adults with synchronous or metachronous oligometastatic (metastasis limited to two sites and amenable for curative/ablative treatment) adenocarcinoma of the foregut without progression after induction chemotherapy and having undetectable ctDNA. These patients will undergo induction chemotherapy and will then be randomized (1:1) to either sequential curative intervention followed by maintenance chemotherapy versus routine continued chemotherapy. The primary endpoint is progression-free survival (PFS), and a total of 48 patients will be enrolled to detect an improvement in the median PFS in the intervention arm with a hazard ratio (HR) of 0.5 with 80% power and a one-sided alpha of 0.1. Secondary endpoints include disease-free survival (DFS) in the intervention arm, overall survival (OS), ctDNA conversion rate pre/post-induction chemotherapy, ctDNA PFS, PFS2, adverse events, quality of life, and financial toxicity.
Discussion
This is the first randomized study that aims to prospectively evaluate the efficacy and safety of surgical/ablative interventions in patients with ctDNA-negative oligometastatic adenocarcinoma of foregut origin post-induction chemotherapy. The results from this study will likely develop pertinent, timely, and relevant knowledge in oncology.
Anzeige
- Titel
- Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels
- Verfasst von
-
Ankit Dhiman, MBBS, MS
Charles C. Vining, MD
Hunter D. D. Witmer, MD
Divya Sood, MD
Ardaman Shergill, MD
Hedy Kindler, MD
Kevin K. Roggin, MD
Mitchell C. Posner, MD
Osmanuddin S. Ahmed, MD
Stanley Liauw, MD
Sean Pitroda, MD
Chih-Yi Liao, MD
Theodore Karrison, PhD
Ralph Weichselbaum, MD
Blase Polite, MD
Oliver S. Eng, MD
Daniel V. T. Catenacci, MD
Kiran K. Turaga, MD, MPH
- Publikationsdatum
- 05.01.2022
- Verlag
- Springer International Publishing
- Erschienen in
-
Annals of Surgical Oncology / Ausgabe 7/2022
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681 - DOI
- https://doi.org/10.1245/s10434-021-11249-7
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
